| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Otaplimastat | SP-8203 hydrochloride; SP8203 HCL; SP-8203 | Phase 3 Clinical | Shin Poong Pharmaceutical Co Ltd | Ischemic Stroke | Details |
| Bis-choline tetrathiomolybdate | ATN-224; WTX-101; ALXN-1840 | Phase 2 Clinical | Wilson Therapeutics | Hepatolenticular Degeneration; Melanoma; Multiple Myeloma; Prostatic Neoplasms | Details |
| Superoxide dismutase (Ube Industries) | r-hSOD; FKU-871 | Phase 2 Clinical | Astellas Pharma Inc, Ube Industries Ltd | Diabetic Neuropathies; Myocardial Ischemia | Details |
| BMX-010 | BMX-010; MnTE-2-PyP; MnTE-2-PyP5+ | Phase 2 Clinical | Duke University | Acne Vulgaris; Dermatitis, Atopic; Psoriasis; Rosacea | Details |
| Tempol | MBM-02; OT-674; NSC-142784; MTS-02; MTS-10; MTS-01; APC-410; APC-400; REC-994; MBM-01; REC-0000994 | Phase 2 Clinical | Mitos | Alopecia; Anus Neoplasms; Ataxia Telangiectasia; Cardiovascular Diseases; Coronavirus Disease 2019 (COVID-19); Drug-Related Side Effects and Adverse Reactions; Glioblastoma; Hemangioma, Cavernous, Central Nervous System; Mucositis; Ototoxicity; Prostatic Neoplasms | Details |
| Superoxide dismutase analogue (LTT Bio-Pharma) | LT-1001; LT-0011; PC-SOD NE; PC-SOD; LT-1002 | Phase 2 Clinical | LTT Bio-Pharma Co Ltd | Colitis, Ulcerative; Idiopathic Pulmonary Fibrosis; Myocardial Infarction; Peripheral Nervous System Diseases; Respiratory Distress Syndrome, Adult; Stroke | Details |
| RAG-17 | RAG-17; RD-12500 | Phase 2 Clinical | Ractigen Therapeutics (Nantong) Co Ltd | Amyotrophic Lateral Sclerosis | Details |
| ALN-SOD | ALN-SOD | Phase 2 Clinical | Alnylam Pharmaceuticals Inc | Amyotrophic Lateral Sclerosis | Details |
| NI-005 | AP-101 (AL-S Pharma); NI-005 | Phase 2 Clinical | Al-S Pharma Ag | Amyotrophic Lateral Sclerosis | Details |
| APB-102 | APB-102; AMT-162 | Phase 2 Clinical | University Of Massachusetts Medical School | Amyotrophic Lateral Sclerosis | Details |
| NAS150 | AEOL-10150; NAS150; NAS-150 | Phase 1 Clinical | Aeolus Pharmaceuticals | Idiopathic Pulmonary Fibrosis; Lung Injury; Neoplasms; Supranuclear Palsy, Progressive | Details |
| INS-1202 | INS1202; INS-1202 | Phase 1 Clinical | Insmed | Amyotrophic Lateral Sclerosis | Details |
| [89Zr]Zr-DFO-AP-101 | Phase 1 Clinical | Université De Sherbrooke | Amyotrophic Lateral Sclerosis; Tooth Diseases | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Orgotein | Approved | Gt Biopharma Inc | Ontosein | Spain | Rheumatic Diseases; Cystitis; Radiation Injuries | null | 1996-01-01 | Cystitis; Radiation Injuries; Rheumatic Diseases | Details | |
| Cupric Sulfate/Manganese sulfate/Selenious acid/Zinc Sulfate | Approved | American Regent Inc | MULTRYS | United States | Dietary Supplement | American Regent Inc | 2020-07-02 | Dietary Supplement | Details | |
| Tofersen | 99mTc-MAG3-BIIB067; ISIS-333611; BIIB-067; SODr/h333611; ISIS-SOD1Rx; IONIS SOD1Rx | Approved | Ionis Pharmaceuticals Inc, Ludwig Institute For Cancer Research | QALSODY, Qalsody, 凯盛迪 | United States | Amyotrophic Lateral Sclerosis | Biogen Ma Inc, Biogen Inc | 2023-04-25 | Amyotrophic Lateral Sclerosis; Familial Amyotrophic Lateral Sclerosis | Details |